Research progress in targeted therapy for thyroid cancer
10.3781/j.issn.1000-7431.2025.2404-0206
- VernacularTitle:甲状腺癌靶向治疗研究进展
- Author:
Wenchao AN
1
;
Wenbin YU
Author Information
1. 内蒙古医科大学研究生院,内蒙古自治区 呼和浩特 010000;北京大学肿瘤医院内蒙古医院头颈外科,内蒙古自治区 呼和浩特 010000
- Publication Type:Journal Article
- Keywords:
Radioiodine refractory differentiated thyroid carcinoma;
Anaplastic thyroid cancer;
Medullary thyroid cancer;
Targeted therapy
- From:
Tumor
2025;45(1):66-74
- CountryChina
- Language:Chinese
-
Abstract:
Thyroid cancer is the most common malignant tumor in head and neck surgery.In recent years,the incidence rate of thyroid cancer has increased rapidly.The traditional treatment is mainly surgical resection,supplemented by 131I treatment,but for advanced or metastatic thyroid cancer,these methods have limited effect.With the deepening of research on the molecular pathogenesis of thyroid cancer,targeted therapy has become a new research hot spot and important treatment method.In recent years,targeted therapy drugs have emerged one after another,such as sorafenib,anlotinib,serpatinib,pratinib,etc.,all of which have shown good efficacy and significantly improved the progression free survival and objective remission rate of patients.However,targeted therapy still faces many problems such as drug resistance,and further research and development of more effective new drugs are needed.This article summarized the research progress of targeted therapy,and aimed to provide reference for the treatment of advanced or iodine refractory thyroid cancer.
